Lafutidine versus Lansoprazole in Combination with Clarithromycin and Amoxicillin for One versus Two Weeks for Helicobacter pylori Eradication in Korea |
| |
| Authors: | Nayoung Kim Soo‐Heon Park Geom Seog Seo Sang Woo Lee Jae Woo Kim Kwang Jae Lee Won‐Chang Shin Tae Nyeun Kim Moo‐In Park Jong‐Jae Park Su Jin Hong Ki‐Nam Shim Sang Wook Kim Yong‐Woon Shin Young‐Woon Chang Hoon Jai Chun Ok‐Jae Lee Won‐Joong Jeon Chan‐Guk Park Chang‐Min Cho Cheol Hee Park Sun Young Won Gin Hyug Lee Kyung Sik Park Jeong Eun Shin Heung Up Kim Joon Yong Park Hiun Suk Chae Geun Am Song Jae Gyu Kim Byung Chul Yoon Sangyong Seol Hyun Chae Jung In‐Sik Chung |
| |
| Institution: | 1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam;2. Department of Internal Medicine, Seoul National University, Seoul;3. Department of Internal Medicine, Catholic University, Seoul;4. Department of Internal Medicine, Wonkwang University, Iksan;5. Department of Internal Medicine, Korea University Hospital, Ansan;6. Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju;7. Department of Gastroenterology, Ajou University, Suwon;8. Department of Internal Medicine, Sanggye Paik Hospital, Inje University, Seoul;9. Department of Internal Medicine, Yeungnam University, Daegu;10. Department of Internal Medicine, Kosin University Gospel Hospital, Busan;11. Department of Internal Medicine, Korea University, Seoul;12. Department of Internal Medicine, Soonchunhyang University, Bucheon;13. Department of Internal Medicine, School of Medicine, Ewha Womans University, Seoul;14. Department of Internal Medicine, Chonbuk National University, Jeonju;15. Department of Internal Medicine, Inha University, Incheon;16. Department of Internal Medicine, Kyung Hee University, Seoul;17. Department of Internal Medicine, Gyeongsang National University, Jinju;18. Department of Internal Medicine, Chungbuk National University, Cheongju;19. Department of Internal Medicine, Chosun University, Gwangju;20. Department of Internal Medicine, Kyungpook National University, Daegu;21. Department of Internal Medicine, Hallym University, Chuncheon;22. Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital, Ilsan;23. Department of Internal Medicine, University of Ulsan, Seoul;24. Department of Internal Medicine, Keimyung University, Daegu;25. Department of Internal Medicine, Dankook University, Cheonan;26. Department of Internal Medicine, Cheju National University, Jeju;27. Department of Internal Medicine, Busan National University, Busan;28. Department of Internal Medicine, Chung‐Ang University, Seoul;29. Department of Internal Medicine, Hanyang University, Seoul;30. Department of Internal Medicine, Inje University, Busan, South Korea |
| |
| Abstract: | Background and Aims: Lafutidine is a novel H2‐receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow. The aim of the present study was to test the efficacy of 7‐ or 14‐day lafutidine–clarithromycin–amoxicillin therapy versus a lansoprazole‐based regimen for Helicobacter pylori eradication. Methods: Four hundred and sixty‐three patients with H. pylori‐infected peptic ulcer disease were randomized to one of four regimens: (1) lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LFT group) or (2) for 14 days (the 14LFT group); (3) lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LPZ group); or (4) for 14 days (the 14LPZ group). The eradication rates, drug compliance, and adverse effects among the four regimens were compared. Results: The eradication rates by the intention‐to‐treat and per‐protocol analyses in the 7LFT and 7LPZ groups were 76.5% and 81.6%, and 76.9% and 82.0% (p = .94 and .95), respectively. The eradication rates by intention‐to‐treat and per‐protocol analyses in the 14LFT and 14LPZ groups were 78.2% and 82.2%, and 80.4% and 85.9% (p = .70 and .49), respectively. The treatment duration for 7 days or 14 days did not affect the eradication rates. In addition, the adverse effect rates and discontinuation rates were similar among the four groups. Furthermore, the ulcer cure rate and symptom response rate were similar in the lafutidine and lansoprazole groups. Conclusion: The results of this study showed that lafutidine–clarithromycin–amoxicillin therapy was a safe and effective as lansoprazole‐based triple therapy for the eradication rate of H. pylori, and could be considered as an additional treatment option. |
| |
| Keywords: | Helicobacter pylori eradication lafutidine triple therapy |
|
|
